European Pharmaceutical Review
DECEMBER 20, 2023
1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted. analysis (Source: L.E.K) About the authors Sean Dyson is a Partner in L.E.K.’s
Medico Reach
AUGUST 1, 2022
Whether you are a start-up looking for investment or are interested in working in venture capital (VC), the worldwide biopharma and MedTech industries are growing. In 2022, over $14 billion was funded in biopharma setup globally, and 37 major IPOs of VC-backed biotech company businesses raised a combined $4.2 CEO : Samuel Isaly.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
OCTOBER 31, 2023
What do the years 2001, 2007, 2014, and 2022 have in common? Investment strategy Industry commentators in the biopharma industry believe the upcoming years are expected to be a period of increased dealmaking activity. In short, the biotech bubble had burst.
Clarivate
MAY 8, 2023
That was the overarching sentiment from the experienced group of biopharma leaders that formed the panel discussion chaired by Mike Ward, Clarivate Global Head of Life Sciences and Healthcare Thought Leadership, at this year’s AngloNordic Life Science conference. Timing is everything. You have to be patiently impatient,” he said.
European Pharmaceutical Review
JULY 20, 2023
Clinical Trials Information System mandatory in EU “[In] the European regulatory framework for advanced therapies, we are guided overall by REGULATION (EC) No 1394/2007,” Warner noted. Although that provides the overall framework for advanced therapies, “this is in the context of marketed advanced therapies”.
PM360
JUNE 16, 2023
In 2007, Alexion set a new pricing milestone of $500,000 annually for Soliris , a treatment for an ultra-rare blood disorder. Funding and access are not new topics of conversation in the rare disease space. Genzyme made headlines in the ’90s when it launched the enzyme replacement therapy Cerezyme for a then-unprecedented $300,000 per year.
Clarivate
APRIL 24, 2023
Key acquisitions by U.S. healthcare organizations Company Founded Type No. Key acquisitions by U.S. healthcare organizations Company Founded Type No.
Expert insights. Personalized for you.
98 
Let's personalize your content